Business
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
CHARLESTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it will present data from its next-generation, proprietary capsid AAV-SLB101 and its cardiac gene therapy pipeline at the Global CardioVascular Clinical Trialists (CVCT) Forum taking place December 8-10, 2025, in Washington, D.C. Gabriel Brooks, M.D., Soli
About this update from Solid Biosciences Inc.
[{"type":"image","alt":"Solid Biosciences Inc.","displaySize":"","headline":null,"caption":"Solid Biosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/5e97e2fffdb55638e3c89b04065944ef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sCFNOglu1.GlZmhoavpsMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5e97e2fffdb55638e3c89b04065944ef","width":300,"height":169}},"lazy":false},{"type":"text","content":"CHARLESTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it will present data from its next-generation, proprietary capsid AAV-SLB101 and its cardiac gene therapy pipeline at the Global CardioVascular Clinical Trialists (CVCT) Forum taking place December 8-10, 2025, in Washington, D.C. Gabriel Brooks, M.D., Solid’s Chief Medical Officer, will exhibit a poster, deliver two presentations and participate in two panel discussions. Dr. Brooks has also been selected as a CVCT faculty member. Additionally, Nicolas Christoforou, Ph.D., Solid’s Head of Discovery and Translational Development, will deliver a presentation on the preclinical development of a gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT) and participate in a panel discussion.","length":958,"tagName":"p"},{"type":"text","content":"The CVCT Forum is an annual, invite-only workshop that aims to cultivate a multi-stakeholder exchange to enhance clinical trials, streamline regulatory approval processes, and facilitate the implementation of trial-based evidence.","length":230,"tagName":"p"},{"type":"text","content":"“We will present data illustrating the potential of our precision genetic approach to cardiac diseases, with a specific focus on the benefits of our proprietary, rationally designed capsid, AAV-SLB101,” said Dr. Brooks. “We look forward to discussing our findings with the community of scientists and trialists as we come together with the goal of transforming the future of cardiovascular disease treatments.”","length":410,"tagName":"p"},{"type":"text","content":"Poster:","length":7,"tagName":"p"},{"type":"list","items":[{"val":[{...